Cell and Gene Therapy 31/01/2018 EMA Hooks Bluebird and Kite with Enticing Regulatory Pathways KITE PHARMA’S RECENT ANNOUNCEMENT OF A MARKETING AUTHORISATION APPLICATION TO THE EMA FOR THEIR LEAD PRODUCT, AXICABTAGENE CILOLEUCEL, HAS RE...
Investment for Advanced Therapies 31/01/2018 Interview: Navigating the IP Landscape and Improving your Chances... Greg Bonfiglio is the founder and managing partner of Proteus, LLC, an investment and advisory firm that provides fund management and...
Investment for Advanced Therapies 31/01/2018 Report: Investment for Advanced Therapies This report provides a comprehensive guide to successfully investing in advanced therapies. It also outlines across six chapters each of the...
Cell and Gene Therapy 23/01/2018 Top 15 Cell and Gene Therapy Biotechs to Watch in 2018 We're keeping tabs on all the innovators and disruptors for you in the field of cell and gene therapies
Immuno-oncology 22/01/2018 15 Immuno-oncology Biotechs to Watch in 2018 We’re keeping tabs on the innovators and disruptors for you
Cell and Gene Therapy 22/01/2018 Regenerative Medicine Contract Manufacturing Organisations in Japan A summary of all of the regenerative medicine CMOs in Japan is presented in this infographic
Cell and Gene Therapy 22/01/2018 Cell and Gene Therapy Manufacturing Capacities in Europe 2017 Without capacity; manufacturing expertise; innovation and partnerships, advanced therapies cannot be commercialised nor delivered to patients ...
Cell and Gene Therapy 22/01/2018 Understanding the layers of complexity and working towards full... One of the main barriers to commercial viability for ATMPs is the supply chain, which contributes significantly to the overall cost of goods ...
Cell and Gene Therapy 18/01/2018 GMP Cell and Gene Therapy Manufacturing in the UK: Facilities,... The cell and gene therapy catapult review of MHRA licensed GMP manufacturing facilities in the UK provides an insightful picture of the capability...
Cell and Gene Therapy 11/01/2018 CRO Selection for Advanced Therapies How do you find the perfect CRO?
Cell and Gene Therapy 16/11/2017 An Investor’s Outlook on the Advanced Therapies Industry with... William Podd gives his perspective on investing in advanced therapies and advice for investors and biotechs alike
Cell and Gene Therapy 06/04/2017 [WEBINAR] Which In-process Bioanalytics do we Really Need for Cell... Explore the shifting paradigm of quality in cell-based therapy manufacturing, with a particular focus on the core concept of embedding quality...
Cell and Gene Therapy 08/03/2017 Interview: Understanding development processes to ensure product... DR Felicia Rosenthal, CEO, Cellgenix discusses raw material for cell and tissue-based products, GMP manufacturing considerations and scale-up...
Cell and Gene Therapy 08/03/2017 Quantitative Understandings of Risk in Cell and Gene Therapies What is risk? How can we accurately understand risk and apply this understanding to inform solutions for investors? There are no easy answers to...
Immuno-oncology 06/03/2017 Systematic Automation of an Autologous Cellular Immunotherapy... As more and more approvals of immuno-oncology therapies become reality, how will these therapies be efficiently and sustainably scaled up and...
